Cargando…
Use of capecitabine in management of early colon cancer
Capecitabine (Xeloda(®), Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic degradation. The role of capecitabine in colorectal cancer has evolved in the last 15 years. In early trials in the metastatic setting, capecitabine...
Autores principales: | Hameed, H, Cassidy, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173019/ https://www.ncbi.nlm.nih.gov/pubmed/21931503 http://dx.doi.org/10.2147/CMR.S12704 |
Ejemplares similares
-
Clinical Management of Localized Colon Cancer with Capecitabine
por: Quidde, J., et al.
Publicado: (2012) -
Capecitabine in the management of colorectal cancer
por: Hirsch, Bradford R, et al.
Publicado: (2011) -
Cessation or dose reduction of Capecitabine due to Complications in Patients with Colon Cancer
por: Sohn, Seung Kook
Publicado: (2010) -
Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy
por: Son, Hyun-Sook, et al.
Publicado: (2009) -
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)